OpGen Inc has filed for an IPO. The number of shares that will be sold as well as its pricing terms have yet to be set. The company plans on listing its stock on the NASDAQ under the ticker symbol “OPGN.” Maxim Group LLC is serving as sole underwriter. Based in Gaithersburg, Maryland, OpGen is a molecular diagnostics company. OpGen’s backers include CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Versant Ventures.
GAITHERSBURG, MD. — OpGen, Inc. today announces the filing of its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to its proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. OpGen is in the process of applying to list its common stock under the symbol “OPGN” on The NASDAQ Capital Market.
Maxim Group LLC is acting as sole book-running manager for the proposed offering.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Maxim Group LLC, 405 Lexington Ave., 2nd Floor, New York, NY, 10174, (800) 724-0761.
OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company’s products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company’s lead product is the Acuitas™ MDRO Gene Test. Products in development include the Acuitas Lighthouse™ bioinformatics platform and the Acuitas Resistome test. In addition, the company has more than 10 years of experience mapping microbial, plant and human genomes.